FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791469895> ?p ?o ?g. }

• W2791469895 endingPage "1731" @default.
• W2791469895 startingPage "1722" @default.
• W2791469895 abstract "Aims To inform patients and their carers about both the probability of reducing glycated haemoglobin (HbA1c) to clinically desirable levels and the sustainability of such control over 2 years with major second‐line antidiabetic therapies, in individual risk scenarios, with and without third‐line intensification. Materials and Methods From US Centricity Electronic Medical Records, 163 081 patients with type 2 diabetes aged 18 to 80 years, who had initiated metformin, intensified their treatment with dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs), sulphonylureas (SUs), insulin or thiazolidinediones (TZDs), and continued second‐line treatment for ≥6 months, were selected. Treatment groups were balanced with regard to baseline characteristics, and glycaemic achievements were estimated using logistic regression analysis. Results With HbA1c concentrations of 58–63.9 mmol/mol (7.5–7.9%) at second‐line treatment initiation, the adjusted probabilities of achieving HbA1c <53 mmol/mol (<7%) at 6 months were 32%, 38%, 39%, 26% and 38% in the SU, DPP‐4 inhibitor, GLP‐1RA, insulin and TZD groups, respectively, while with baseline HbA1c concentrations of 64–75 mmol/mol (8–9%), the corresponding probabilities of reducing HbA1c to <58 mmol/mol (<7.5%) were 38%, 44%, 40%, 34% and 42%, respectively. In these baseline HbA1c categories, the adjusted probabilities of sustaining HbA1c achievements over 2 years were higher in the GLP‐1RA and TZD groups, compared with the SU and insulin groups ( P < .01). With baseline HbA1c concentrations of 75.1–108 mmol/mol (9.1–12%) 38% of patients achieved an HbA1c concentration <58 mmol/mol (<7.5%) at 6 months. The adjusted probability of sustaining this control over 2 years was higher in the incretin and TZD groups (range 62%‐75%), while insulin and SUs offered lower chances of sustainable control (range 54%‐56%). Conclusions Patients treated with second‐line incretins and TZDs had a significantly higher probability of achieving and sustaining glycaemic control over 2 years without further intensification, compared with those treated with SUs or insulin." @default.
• W2791469895 created "2018-03-29" @default.
• W2791469895 creator A5012761737 @default.
• W2791469895 creator A5024475260 @default.
• W2791469895 creator A5070289715 @default.
• W2791469895 creator A5075417158 @default.
• W2791469895 date "2018-04-15" @default.
• W2791469895 modified "2023-09-27" @default.
• W2791469895 title "Long‐term sustainability of glycaemic achievements with second‐line antidiabetic therapies in patients with type 2 diabetes: <scp>A</scp> real‐world study" @default.
• W2791469895 cites W1462529649 @default.
• W2791469895 cites W1972406202 @default.
• W2791469895 cites W1975588287 @default.
• W2791469895 cites W1975777549 @default.
• W2791469895 cites W1985772842 @default.
• W2791469895 cites W1988007297 @default.
• W2791469895 cites W1996203790 @default.
• W2791469895 cites W2028040032 @default.
• W2791469895 cites W2030852056 @default.
• W2791469895 cites W2061326496 @default.
• W2791469895 cites W2107222124 @default.
• W2791469895 cites W2127125241 @default.
• W2791469895 cites W2168639902 @default.
• W2791469895 cites W2298126719 @default.
• W2791469895 cites W2324211711 @default.
• W2791469895 cites W2340898396 @default.
• W2791469895 cites W2492974594 @default.
• W2791469895 cites W2507907266 @default.
• W2791469895 cites W2523617397 @default.
• W2791469895 cites W2586927659 @default.
• W2791469895 cites W2736945114 @default.
• W2791469895 cites W2743088090 @default.
• W2791469895 cites W2745170751 @default.
• W2791469895 cites W2755083612 @default.
• W2791469895 cites W2767408736 @default.
• W2791469895 cites W2917198334 @default.
• W2791469895 cites W4239837977 @default.
• W2791469895 doi "https://doi.org/10.1111/dom.13288" @default.
• W2791469895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29536608" @default.
• W2791469895 hasPublicationYear "2018" @default.
• W2791469895 type Work @default.
• W2791469895 sameAs 2791469895 @default.
• W2791469895 citedByCount "11" @default.
• W2791469895 countsByYear W27914698952018 @default.
• W2791469895 countsByYear W27914698952019 @default.
• W2791469895 countsByYear W27914698952020 @default.
• W2791469895 countsByYear W27914698952021 @default.
• W2791469895 countsByYear W27914698952022 @default.
• W2791469895 crossrefType "journal-article" @default.
• W2791469895 hasAuthorship W2791469895A5012761737 @default.
• W2791469895 hasAuthorship W2791469895A5024475260 @default.
• W2791469895 hasAuthorship W2791469895A5070289715 @default.
• W2791469895 hasAuthorship W2791469895A5075417158 @default.
• W2791469895 hasBestOaLocation W27914698952 @default.
• W2791469895 hasConcept C126322002 @default.
• W2791469895 hasConcept C134018914 @default.
• W2791469895 hasConcept C151956035 @default.
• W2791469895 hasConcept C2776398474 @default.
• W2791469895 hasConcept C2777180221 @default.
• W2791469895 hasConcept C2779306644 @default.
• W2791469895 hasConcept C2780323712 @default.
• W2791469895 hasConcept C2909938374 @default.
• W2791469895 hasConcept C555293320 @default.
• W2791469895 hasConcept C71924100 @default.
• W2791469895 hasConcept C90924648 @default.
• W2791469895 hasConcept C98274493 @default.
• W2791469895 hasConceptScore W2791469895C126322002 @default.
• W2791469895 hasConceptScore W2791469895C134018914 @default.
• W2791469895 hasConceptScore W2791469895C151956035 @default.
• W2791469895 hasConceptScore W2791469895C2776398474 @default.
• W2791469895 hasConceptScore W2791469895C2777180221 @default.
• W2791469895 hasConceptScore W2791469895C2779306644 @default.
• W2791469895 hasConceptScore W2791469895C2780323712 @default.
• W2791469895 hasConceptScore W2791469895C2909938374 @default.
• W2791469895 hasConceptScore W2791469895C555293320 @default.
• W2791469895 hasConceptScore W2791469895C71924100 @default.
• W2791469895 hasConceptScore W2791469895C90924648 @default.
• W2791469895 hasConceptScore W2791469895C98274493 @default.
• W2791469895 hasIssue "7" @default.
• W2791469895 hasLocation W27914698951 @default.
• W2791469895 hasLocation W27914698952 @default.
• W2791469895 hasLocation W27914698953 @default.
• W2791469895 hasOpenAccess W2791469895 @default.
• W2791469895 hasPrimaryLocation W27914698951 @default.
• W2791469895 hasRelatedWork W1983641721 @default.
• W2791469895 hasRelatedWork W2005084305 @default.
• W2791469895 hasRelatedWork W2026226896 @default.
• W2791469895 hasRelatedWork W2033313326 @default.
• W2791469895 hasRelatedWork W2044572938 @default.
• W2791469895 hasRelatedWork W2048352852 @default.
• W2791469895 hasRelatedWork W2066345847 @default.
• W2791469895 hasRelatedWork W2086036309 @default.
• W2791469895 hasRelatedWork W2095179743 @default.
• W2791469895 hasRelatedWork W2744240433 @default.
• W2791469895 hasVolume "20" @default.
• W2791469895 isParatext "false" @default.
• W2791469895 isRetracted "false" @default.
• W2791469895 magId "2791469895" @default.
• W2791469895 workType "article" @default.